AstraZeneca Annual Report and Additional Information Form 20-F Information 2004 for US Investors 125 Additional Information for US Investors Introduction recorded as goodwill.
The amount allocated On disposal of a business, the gain or loss The accompanying consolidated Financial to in-process research and development under US GAAP may differ from that under Statements included in this Annual Report was, as required by US GAAP, expensed UK GAAP due principally to goodwill are prepared in accordance with UK GAAP.
immediately in the first reporting period after capitalised and amortised, together with the There are certain significant differences the business combination.
Fair value appropriate share of other differences between UK GAAP and US GAAP which adjustments to the recorded amount of between UK and US accounting principles affect AstraZenecas net income and inventory were expensed in the period recognised previously.
shareholders equity and, on pages 125 to the inventory was utilised.
Additional 135, additional information under US GAAP amortisation and depreciation have Capitalisation of interest is set out as follows: also been recorded in respect of the fair AstraZeneca does not capitalise interest in its value adjustments to tangible and UK GAAP Financial Statements.
US GAAP summary of differences between UK intangible assets.
requires interest incurred as part of the cost and US GAAP accounting principles: of constructing fixed assets to be capitalised page 125 In the consolidated Financial Statements and amortised over the life of the asset.
prepared under UK GAAP, goodwill arising net income: page 128 on acquisitions made prior to 1 January 1998 Dividends accounted for under the purchase method Under UK GAAP, Ordinary Share dividends US GAAP condensed consolidated has been eliminated against shareholders proposed are provided for in the year in statement of operations: page 129 equity.
Under the requirements of UK respect of which they are recommended by Financial Reporting Standard 10 Goodwill the Board of Directors for approval by the US GAAP statement of comprehensive and Intangible Assets, goodwill on shareholders.
Under US GAAP, such income: page 129 acquisitions made after 1 January 1998 is dividends are not provided for until declared capitalised and amortised over its estimated by the Board.
stock-based compensation: page 130 useful life which is generally presumed not to exceed 20 years.
UK GAAP requires that Deferred taxation pension and post-retirement benefits: on subsequent disposal or termination of a Deferred taxation is provided on a full liability page 131 previously acquired business, any goodwill basis under US GAAP, which permits previously taken directly to shareholders deferred tax assets to be recognised if their taxation: page 133 equity is then charged in the income realisation is considered to be more likely statement against the profit or loss on than not.
Under current UK GAAP, full shareholders equity: page 134 disposal or termination.
Up until 1 January provision is also made although there are a 2002, under US GAAP, goodwill was number of different bases on which this acquired intangible assets and goodwill: required to be capitalised and amortised.
calculation is made, for example rolled over page 134 Now, instead of being amortised, goodwill capital gains.
is tested annually for impairment.
US GAAP condensed consolidated Pension and post-retirement benefits statement of cash flows: page 135 Identifiable intangible assets, which There are four main differences between principally include patents, know-how current UK GAAP and US GAAP in Differences between UK and US and product registrations, are amortised accounting for pension costs: accounting principles over their estimated useful lives which vary between five years and 20 years with a i US GAAP requires measurements of Purchase accounting adjustments weighted average life of approximately plan assets and obligations to be made Under UK GAAP, the merger of Astra and 13 years.
as at the date of the financial statements Zeneca was accounted for as a merger of or a date not more than three months equals pooling-of-interests.
Under US At 31 December 2004 and 2003 under US prior to that date.
Under UK GAAP, GAAP the merger was accounted for as the GAAP, shareholders equity includes calculations may be based on the results acquisition of Astra by Zeneca using capitalised goodwill of $16,143m and of the latest actuarial valuation: purchase accounting.
Under purchase $15,306m respectively net of amortisation accounting, the cost of the investment is and impairment of $2,698m and $2,596m ii US GAAP mandates a particular calculated at the market value of the shares and capitalised identifiable intangible assets actuarial method the projected unit issued together with other incidental costs of $8,854m and $9,536m respectively net credit method and requires that each and the assets and liabilities of the acquired of amortisation and impairment of $8,514m significant assumption necessary to entity are recorded at fair value.
Goodwill on businesses determine annual pension costs reflects the fair value exercise, increases in the values disposed of is charged to the gain or loss best estimates solely with regard to that of Astras tangible fixed assets and inventory on disposal.
UK GAAP does were recognised and values attributed to its not mandate a particular method, but in-process research and development and requires that the method and existing products, together with appropriate assumptions taken as a whole should be deferred taxation effects.
The difference compatible and lead to the actuarys best between the cost of investment and the fair estimate of the cost of providing the value of the assets and liabilities of Astra was benefits promised: AstraZeneca Annual Report and Additional Information 126 Form 20-F Information 2004 for US Investors Additional Information for US Investors continued Differences between UK and US such deferral is not permitted except in between the standards relate to accounting principles continued certain defined circumstances.
Under FRS 1, the Company presents its cash flows for a operating iii under US GAAP, a negative pension cost Financial instruments and hedging activities: b dividends received from joint may arise where a significant activities ventures and associates: c returns on unrecognised net asset or gain exists at Under US GAAP, all derivative instruments investments and servicing of finance: the time of implementation.
This is should be recognised as assets or liabilities in d tax paid: e capital expenditure and required to be amortised on a straightthe balance sheet at fair value.
Gains and financial investment: f acquisitions and line basis over the average remaining losses are recognised in net income unless disposals: g dividends paid to shareholders: service period of employees.
Under UK they are regarded as hedges.
Under UK h management of liquid resources: and GAAP, AstraZenecas policy is not to GAAP, these instruments are measured at i financing.
95 requires only three recognise pension credits in its Financial cost and gains or losses deferred until the categories of cash flow activity being Statements unless a refund of, or underlying transactions occur.
reduction in, contributions is likely: and Under US GAAP, marketable securities are Cash flows from taxation, returns on iv under US GAAP, a minimum pension recognised at fair value, with movements in investments and servicing of finance and liability is recognised through other fair value taken to a separate component of dividends received from joint ventures and comprehensive income in certain equity.
Under UK GAAP, such investments associates under FRS 1 would be included circumstances when there is a deficit of are held at cost.
as operating activities under SFAS No.
95: plan assets relative to the accumulated capital expenditure and financial investment benefits obligation.
Under UK GAAP, Deferred income and acquisitions and disposals would be there is no such requirement.
Under UK GAAP, profits or losses from the included as investing activities: and sale of product related intangible assets are distributions would be included as a Restructuring costs generally taken to other operating income at financing activity under SFAS No.
Under Under UK GAAP, provisions are made for disposal and are stated after taking account FRS 1 cash comprises cash in hand and restructuring costs once a detailed formal of product disposal costs and costs of minor deposits repayable on demand, less plan is in place and valid expectations have outstanding obligations.
Under US GAAP, overdrafts repayable on demand: and liquid been raised in those affected that the such profits are deferred and recognised in resources comprise current asset restructuring will be carried out.
US GAAP the income statement in subsequent periods investments held as readily disposable stores requires a number of specific criteria to be until all disposal obligations and of value.
95 cash met before such costs can be recognised as commitments have been completed.
equivalents, comprising short term highly an expense.
Among these are the liquid investments, generally with original requirements that costs associated with exit Stock-based compensation maturities of three months or less, are or disposal activities are recognised when In the Groups Financial Statements prepared grouped together with cash: short term the costs are incurred rather than at the date under UK GAAP, no cost is accrued for the borrowings repayable on demand would not of commitment to an exit or disposal plan.
To share options awarded to employees under be included within cash and cash equivalents the extent that restructuring costs are related the AstraZeneca Share Option Plan and the and movements on those borrowings would to the activities of the acquired company, US AstraZeneca Savings-Related Share Option be included in financing activities.
GAAP allows them to be recognised as a Plan as the exercise price is equivalent to the liability upon acquisition.
market value at the date of grant.
Under US New accounting standards GAAP, the cost is calculated as the difference FIN No.
46R Consolidation of Variable Intangible assets between the option price and the market Interest Entities VIE is intended to address Under UK GAAP, AstraZeneca capitalises price at the date of grant or, for variable perceived weaknesses in accounting for certain defined software costs and amortises plans, at the end of the reporting period until special purpose or off-balance sheet entities these over five years.
Under US GAAP, measurement date.
Under the requirements and provides guidance on identifying the software costs are generally capitalised and of APB Opinion No.
25 any compensation primary beneficiary resulting from amortised over three to five years.
cost would be charged over the period from arrangements or financial interests as the date the options are granted to the date opposed to voting rights.
If a party is a Under UK GAAP certain payments for rights they are first exercisable.
Under US GAAP, in primary beneficiary then the assets, liabilities to compounds in development are the net income reconciliation, the Group has and results of the VIE should be included in capitalised.
Under US GAAP these adjusted for stock-based compensation the consolidated financial statements of the payments are expensed.
costs calculated under APB Opinion No.
46R applied to all VIEs or potential VIEs referred to as special purpose Foreign exchange Statement of cash flows: Basis of entities for periods ending on or after 15 Under UK GAAP, unrealised gains and losses preparation December 2003.
Adoption for all other on foreign currency transactions to hedge AstraZenecas statement of Group cash flow entities was required for periods ending on or anticipated, but not firmly committed, foreign is prepared in accordance with UK Financial after 15 March 2004.
46R did not currency transactions may be deferred and Reporting Standard 1 Revised 1996 FRS have a material effect on the results or net accounted for at the same time as the 1, whose objective and principles are similar assets of AstraZeneca.
Under US GAAP, to those set out in SFAS No.
The principal differences AstraZeneca Annual Report and Additional Information Form 20-F Information 2004 for US Investors 127 In March 2004, the Emerging Issues Task In December 2004, the FASB issued SFAS Force EITF issued EITF Issue No.
152 Accounting for Real Estate TimeParticipating Securities and the Two-Class sharing Transactions, an amendment of Method under FASB Statement No.
66 and 67 which Earnings per Share.
This guidance provides that real estate time-sharing addressed changes in the reporting and transactions should be accounted for as calculation requirements for earnings per non-retail land sales.
152 is share, setting out the method to be used effective for fiscal years beginning after when a company has granted holders of any 15 June 2005.
The adoption of SFAS form of security rights to participate in the No.
152 is not expected to have a material earnings of the company along with the effect on the net assets or results of participation rights of common stockholders.
The adoption of EITF 03-6 had no effect on AstraZeneca.
In December 2004, the FASB issued SFAS No.
153 Exchanges of Non-monetary In June 2004, the EITF issued EITF Issue No.
Assets, an amendment of APB Opinion No.
03-1 The Meaning of Other Than Temporary 29 which replaces the current exception Impairment and Its Application to Certain from fair value measurement for nonInvestments.
The guidance details how to monetary exchanges of similar productive determine the meaning of other than assets with a general exception from fair temporary impairment and its application to value measurement for exchanges of nondebt and equity securities within the scope of monetary assets that do not have SFAS No.
115 Accounting for Certain commercial substance.
153 shall Investments in Debt and Equity Securities be applied prospectively and is effective for SFAS No.
115 and to equity securities that non-monetary asset exchanges occurring in are not subject to the scope of SFAS No.
fiscal periods beginning after 15 June 2005.
115 and are not accounted for under the The adoption of SFAS No.
153 is not equity method of accounting.
The guidance expected to have a material effect on the also includes accounting considerations results or net assets of AstraZeneca.
subsequent to the recognition of an impairment other than temporary and In December 2004, the FASB issued SFAS requires certain disclosures about unrealised No.
123 R Share-Based Payment that will losses that have not been recognised as require compensation costs related to shareother than temporary impairments.
These based payment transactions to be disclosure requirements became effective for recognised in the financial statements.
With periods ended prior to 30 June 2004.
The limited exceptions, the amount of introduction of recognition and compensation cost will be measured based measurement guidance of EITF 03-1 has on the grant-date fair value of the equity or been deferred.
The disclosure requirements liability instruments issued.
In addition, liability did not have a significant effect on awards will be remeasured each reporting AstraZeneca: it is not expected that the period.
Compensation cost will be recognition and measurement requirements recognised over the period that an employee will have a material impact either.
provides service in exchange for the award.
123, In November 2004, the FASB issued SFAS Accounting for Stock-Based No.
151 Inventory Costs to clarify the Compensation, and supersedes APB accounting for abnormal amounts of idle Opinion No.
25, Accounting for Stock facility expense, freight, handling costs, and Issued to Employees.
The effective date wasted material spoilage.
123 R is accounting periods effective for inventory costs incurred during commencing on or after 15 June 2005. fiscal years beginning after 15 June 2005.
The standard should be applied using the The adoption of SFAS No.
151 is not modified prospective method although there expected to have a material effect on the are transitional arrangements for modified results or net assets of AstraZeneca.
retrospective application if the disclosure or recognition requirements of SFAS No.
AstraZeneca has not yet determined the effect of the adoption of SFAS No.
123 R. AstraZeneca Annual Report and Additional Information 128 Form 20-F Information 2004 for US Investors Additional Information for US Investors continued Differences between UK and US accounting principles continued Net income As a result of the significant difference between the UK GAAP and US GAAP treatment of the combination of Astra and Zeneca in the year of acquisition, and in the results of preceding periods, condensed statements of operations and cash flow under US GAAP have been prepared for the benefit of US investors.
The following is a summary of the adjustments to net income and shareholders equity which would have been required if US GAAP had been applied instead of UK GAAP.
2004 2003 2002 $m $m $m Net income, as shown in the consolidated statements of income before exceptional items 3,527 3,036 3,186 Exceptional items after tax 286 350 Net income for the period under UK GAAP 3,813 3,036 2,836 Adjustments to conform to US GAAP Purchase accounting adjustments including goodwill and intangibles Deemed acquisition of Astra Amortisation and other acquisition adjustments 1,014 952 864 Others 49 59 55 Capitalisation, less disposals and amortisation of interest 1 17 46 Deferred taxation On fair values of Astra 283 266 239 Others 90 91 99 Pension and other post-retirement benefits expense 52 43 46 Software costs 6 18 46 Stock-based compensation 11 12 33 Fair value of financial instruments 94 10 93 Research and development 31 Deferred income recognition 14 61 Unrealised losses on foreign exchange and others 9 18 1 Net income in accordance with US GAAP 3,051 2,268 2,307 AstraZeneca Annual Report and Additional Information Form 20-F Information 2004 for US Investors 129 Differences between UK and US accounting principles continued US GAAP Condensed Consolidated Statement of Operations 2004 2003 2002 For the years ended 31 December $m $m $m Sales 21,426 18,849 17,841 Cost of sales 5,150 4,469 4,520 Distribution costs 177 162 141 Research and development 3,858 3,451 3,069 Selling, general and administrative expenses 7,889 6,941 6,165 Amortisation of intangibles 953 881 1,052 Other income 534 225 308 Operating income 3,933 3,170 3,202 Net interest expense income 1 63 140 Income from continuing operations before taxation 3,932 3,233 3,342 Taxes on income from continuing operations 881 965 1,035 Net income from continuing operations 3,051 2,268 2,307 Net income for the year 3,051 2,268 2,307 Weighted average number of $0.25 Ordinary Shares in issue millions 1,673 1,709 1,733 Dilutive impact of share options outstanding millions 2 32 Diluted weighted average number of $0.25 Ordinary Shares in accordance with US GAAP millions 1,675 1,712 1,735 Net income per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted $1.82 $1.33 $1.33 US GAAP Statement of Comprehensive Income 2004 2003 2002 For the years ended 31 December $m $m $m Net income for the year 3,051 2,268 2,307 Exchange gains, net of tax 2,106 3,635 2,919 Other movements, net of tax 20 81 73 Total comprehensive income 5,177 5,822 5,153 Other movements in 2004 include a reduction in the minimum liability under SFAS No.
87 Employers Accounting for Pensions from $39m to $36m.
Tax effects on exchange gains losses were $ 82 m and on other movements $27m.
The cumulative exchange gains and losses net of tax on the translation of foreign currency financial statements under US GAAP are set out in the following note: 2004 2003 2002 For the years ended 31 December $m $m $m Balance at 1 January 2,236 1,399 4,318 Movement in year 2,106 3,635 2,919 Balance at 31 December 4,342 2,236 1,399 The cumulative total of other movements net of tax at 31 December 2004 was a charge of $134m 2003 $154m, 2002 $73m.
AstraZeneca Annual Report and Additional Information 130 Form 20-F Information 2004 for US Investors Additional Information for US Investors continued Differences between UK and US accounting principles continued Stock-based compensation In the Groups Financial Statements prepared under UK GAAP, no cost is accrued for the share options awarded to employees under the AstraZeneca Share Option Plan, and the AstraZeneca Savings-Related Share Option Plan as the exercise price is equivalent to the market value at the date of grant.
Under US GAAP the cost is calculated as the difference between the option price and the market price at the date of grant or, for variable plans, at the end of the reporting period until measurement date.
Under the requirements of APB Opinion No.
25 any compensation cost would be amortised over the period from the date the options are granted to the date they are first exercisable.
Under US GAAP in the net income reconciliation, the Group has adjusted for stock compensation costs as calculated under APB Opinion No.
123 Accounting for Stock-Based Compensation sets out an alternative methodology for recognising the compensation cost based on the fair value at grant date.
Had the Group adopted this methodology, the incremental effect on net income under US GAAP is shown below: 2004 2003 2002 $m $m $m Net income under US GAAP as reported 3,051 2,268 2,307 Compensation cost under APB No.
25 11 12 33 Compensation cost under SFAS No.
123 147 154 122 Pro forma net income 2,893 2,126 2,152 Pro forma net income per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted : As reported $1.82 $1.33 $1.33 Pro forma $1.73 $1.24 $1.24 The fair value of options granted is estimated, based on the stock price at the grant date, using the Black-Scholes option pricing model with the following assumptions: 2004 2003 2002 Dividend yield 2.3% 2.0% 1.6% Expected volatility 25.0% 25.0% 30.0% Risk-free interest rate 3.5% 4.3% 5.2% Expected lives: AstraZeneca Share Option Plan 6.0 years 6.0 years 6.0 years Expected lives: SAYE Plan 3.8 years 4.3 years 4.3 years AstraZeneca Annual Report and Additional Information Form 20-F Information 2004 for US Investors 131 Differences between UK and US accounting principles continued Pension and post-retirement benefits For the purposes of US GAAP, the pension information as set out in Note 28 in respect of the UK retirement plans and of the retirement plans of the non-UK subsidiaries has been restated in the following tables in accordance with the requirements of SFAS No.
132 Employers Disclosures about Pensions and Other Postretirement Benefits, an amendment of FASB Statements No.
These plans comprise substantially all of the actuarial liabilities of all AstraZeneca retirement plans.
The changes in projected benefit obligations, plan assets and details of the funded status of these retirement plans, together with the changes in the accumulated other post-retirement benefit obligations, under SFAS No.
132 are as follows: Other Pension post-retirement benefits benefits Change in projected benefit obligation 2004 2003 2004 2003 $m $m $m $m Benefit obligation at beginning of year 7,416 5,943 242 210 Service cost 229 171 11 9 Interest cost 385 329 14 14 Participant contributions 30 26 1 1 Actuarial loss gain 328 545 3 24 Special termination benefits Settlement and curtailment 10 5 Benefits paid 281 245 18 19 Exchange 590 642 2 3 Benefit obligation at end of year 8,707 7,416 249 242 Other Pension post-retirement benefits benefits Change in plan assets 2004 2003 2004 2003 $m $m $m $m Fair value at beginning of year 5,905 4,549 195 133 Actual return on plan assets 565 590 22 35 Group contribution 280 489 17 43 Participant contributions 30 26 1 Settlement and curtailment Benefits paid 281 245 17 17 Exchange 473 496 Fair value of plan assets at end of year 6,972 5,905 217 195 Funded status of plans 1,735 1,511 32 47 Unrecognised net loss 1,644 1,503 29 36 Prior service cost not recognised 15 25 11 9 Unrecognised net obligation on implementation 1 1 25 29 77 16 11 9 Adjustments to recognise minimum liability: Intangible assets 36 39 Accumulated other comprehensive income 217 260 Accrued benefit asset liability 330 283 11 9 At 31 December 2004, the projected benefit obligation, accumulated benefit obligation and fair value of the plan assets in respect of the pension plans above with accumulated benefit obligations in excess of plan assets were $6,699m, $5,800m and $5,220m, 2003 $5,779m, $4,961m and $4,415m respectively.
The total of accumulated benefit obligations for the pension plans was $7,443m 2003 $6,239m.
The measurement date for the plan assets and benefit obligations set out above was 31 December 2004.
Contributions to the plans in 2005 are estimated to be $224m.
AstraZeneca Annual Report and Additional Information 132 Form 20-F Information 2004 for US Investors Additional Information for US Investors continued Differences between UK and US accounting principles continued Assumed discount rates and rates of increase in remuneration used in calculating the projected benefit obligations together with long term rates of return on plan assets vary according to the economic conditions of the country in which the retirement plans are situated.
The weighted average rates used for calculation of year end benefit obligations and forecast benefit cost in the retirement plans and other benefit obligations for SFAS No.
132 purposes were as follows: Pension benefits Other post-retirement benefits 2004 2003 2002 2004 2003 2002 % %% % %% Discount rate 5.2 5.5 5.8 5.7 5.9 6.6 Long term rate of increase in remuneration 3.9 4.0 4.1 n a n a n a Expected long term return on assets 6.8 6.6 6.4 7.8 7.8 7.8 The Group has assumed a long term rate of increase in healthcare costs of 8%, reducing to 4%.
Pension benefits Other post-retirement benefits 2004 2003 2002 2004 2003 2002 $m $m $m $m $m $m Net periodic cost Service cost present value of benefits accruing during the year 229 171 146 11 98 Interest cost on projected benefit obligations 385 329 287 14 14 14 Expected return on assets 406 308 276 15 14 Net amortisation and deferral 76 45 34 3 2 1 Net periodic cost for the year 284 237 191 13 11 21 It is estimated that a one percentage point change in the weighted average healthcare costs trend would have the following effects on the accumulated benefit obligation and net periodic cost at 31 December 2004: One percentage point Increase Decrease $m $m Accumulated benefit obligation 15 13 Net periodic cost 2 2 The weighted average allocation of pension and other post-retirement plan assets was as follows: 2004 2003 % % Equities 49.7 49.2 Bonds 36.0 48.8 Other 14.3 2.0 The benefits expected to be paid in the future are as follows: $m 2005 326 2006 337 2007 349 2008 362 2009 376 2010 2014 1,761 AstraZeneca Annual Report and Additional Information Form 20-F Information 2004 for US Investors 133 Differences between UK and US accounting principles continued Taxation 2004 2003 2002 Years ended 31 December $m $m $m Taxes on income from continuing operations UK taxation Corporation tax 379 138 165 Double taxation relief 22 23 7 Adjustment in respect of prior period 178 Deferred taxation 47 88 40 Overseas taxation Overseas taxes 992 878 921 Adjustments in respect of prior periods 7 35 51 Deferred taxation 250 151 33 Share of taxation of joint ventures and associates Taxes on income from continuing operations 881 965 1,035 The table below reconciles the UK statutory tax charge with the Groups actual charge on income from continuing operations.
2004 2003 2002 Years ended 31 December $m $m $m Income on continuing operations 3,932 3,233 3,342 Taxation charge at UK corporation tax rate of 30% for 2004 30% for 2003, 30% for 2002 1,180 970 1,002 Differences in effective overseas tax rates 27 41 6 Items not deductible for tax purposes 40 89 83 Items not chargeable for tax purposes 71 88 110 Adjustments in respect of prior periods 171 35 51 Exceptional items 124 105 Tax on income from continuing operations 881 965 1,035 In 2004, claims amounting to $nil 2003 $95m for tax relief were made arising as a result of a restructuring of the AMI joint venture in 1998.
Under US GAAP, these reliefs are adjusted against the goodwill arising on the restructuring and included in other adjustments.
AstraZeneca Annual Report and Additional Information 134 Form 20-F Information 2004 for US Investors Additional Information for US Investors continued Differences between UK and US accounting principles continued Shareholders equity 2004 2003 $m $m Total shareholders equity under UK GAAP 14,418 13,178 Adjustments to conform to US GAAP Purchase accounting adjustments including goodwill and intangibles Deemed acquisition of Astra Goodwill 15,099 14,311 Tangible and intangible fixed assets 6,988 7,661 Others 206 145 Capitalisation, less disposals and amortisation of interest 254 255 Deferred taxation On fair value of Astra 2,134 2,313 Others 92 207 Dividend 1,061 914 Pension and other post-retirement benefits expense 573 534 Software costs capitalised 52 46 Fair value of financial instruments 2 109 Deferred income recognition Others 33 89 Shareholders equity in accordance with US GAAP 35,314 33,654 Acquired intangible assets Details of the carrying amounts of intangible fixed assets and past and projected amortisation expenses are set out below.
2004 2003 Gross Gross carrying Accumulated carrying Accumulated amount amortisation amount amortisation $m $m $m $m Product rights 14,590 6,744 13,733 5,274 Marketing and distribution rights 1,729 1,043 1,659 831 Software 589 367 462 305 Others 460 360 421 329 Total 17,368 8,514 16,275 6,739 Aggregate amortisation expense $m For year ended 31 December 2004 1,316 For year ended 31 December 2003 1,245 For year ended 31 December 2002 1,154 Estimated amortisation expense $m For year ended 31 December 2005 1,316 For year ended 31 December 2006 1,304 For year ended 31 December 2007 1,216 For year ended 31 December 2008 1,216 For year ended 31 December 2009 1,216 AstraZeneca Annual Report and Additional Information Form 20-F Information 2004 for US Investors 135 Differences between UK and US accounting principles continued The weighted average amortisation period in respect of each class of intangible asset is as follows: Product rights 13 years Marketing and distribution rights 16 years Software 4 years Other 8 years Goodwill The changes in the carrying amount of goodwill for the two years ended 31 December 2004 were as follows: $m Balance as at 1 January 2003 13,647 Acquired 1 Exchange adjustments 1,658 Balance as at 1 January 2004 15,306 Exchange and other movements 837 Balance as at 31 December 2004 16,143 US GAAP Condensed Consolidated Statement of Cash Flows 2004 2003 2002 For the years ended 31 December $m $m $m Cash flows from operating activities 4,842 3,416 4,833 Cash flows from investing activities Movement in short term investments and fixed deposits 862 771 806 New fixed asset investments 117 120 1 Disposal of fixed assets 35 38 66 Acquisitions and disposals 355 80 Capital expenditure 1,183 1,515 1,608 Net cash outflows from investing activities 1,772 746 2,349 Net cash flow before financing 3,070 2,670 2,484 Cash flows from financing activities Equity dividends paid 1,378 1,222 1,234 Re-purchase of AstraZeneca PLC Ordinary Shares 2,110 1,107 1,154 Net increase decrease in short term borrowings 2 13 New loans loans repaid 725 345 105 Net cash outflows from financing activities 2,761 2,674 2,506 Increase decrease in cash 309 4 22 Cash: At 1 January 581 524 510 Increase decrease in cash 309 4 22 Exchange movements 23 61 36 At 31 December 913 581 524 Interest paid was $62m in 2004 2003 $32m, 2002 $96m.
